论文部分内容阅读
目的 探讨p185和p53在骨巨细胞瘤 (GCT)的表达及GCT病理分级和复发的关系。方法 应用SP免疫组织化学方法检测 p53和 p185在 52例GCT(GCT按Jaffe分级 :Ⅰ级 15例、Ⅱ级 2 5例、Ⅲ级 12例 )中的表达。结果 11例 p185表达呈阳性 ,阳性率 2 1 2 % ,14例 p53表达阳性 ,阳性率 2 6 9%。其阳性表达与病理分级差异均无显著性 (P >0 0 5)。p53和 p185在复发和无复发的病例中 ,阳性表达率分别为 38 5%、15 4 %和4 6 2 %、2 0 5%。两者同时阳性表达的有 4例 ,p53和p185同时过表达与GCT病理分级无关 (P >0 0 5)而与其复发有显著性差异 (χ2 =6 12 5,P <0 0 5)。结论 p185和p53在GCT中的表达与病理分级无关而与其复发有关。所以 ,我们认为骨巨细胞瘤时 p53和 p185过度表达的临床意义有待进一步研究。
Objective To investigate the relationship between the expression of p185 and p53 in giant cell tumor of bone (GCT) and the pathological grade and recurrence of GCT. Methods SP immunohistochemistry was used to detect the expression of p53 and p185 in 52 cases of GCT (Jaffe classification of GCT: Ⅰ grade 15 cases, Ⅱ 25 cases, Ⅲ grade 12 cases). Results The positive expression rate of p185 in 11 cases was 21.2%. The positive expression rate of p53 in 14 cases was 269%. There was no significant difference between the positive expression and pathological grade (P> 0.05). The positive rates of p53 and p185 were 38 5%, 154%, 462% and 25% respectively in cases of recurrence and no recurrence. There were 4 cases with positive expression of p53 and p185 at the same time. The overexpression of p53 and p185 was not associated with the pathological grade of GCT (P> 0.05), but significant difference was found between them (χ2 = 6 12 5, P <0 05). Conclusion The expression of p185 and p53 in GCT has nothing to do with the pathological grade but relapse. Therefore, we believe that the clinical significance of overexpression of p53 and p185 in giant cell tumor remains to be further studied.